OsteoarthritisNCT07660081
Effects of Acetyl L-Carnitine Supplementation on Clinical, Metabolic and Inflammatory Symptoms in Obese, Diabetic, Postmenopausal Women With Osteoarthritis
A study testing Acetyl-l-carnitine in people with Osteoarthritis and Type 2 Diabetes, run by Khyber Medical University Peshawar at 1 site in Pakistan.
Trial summary
OA is a degenerative bone disease more common in postmenopausal women. Diabetes and obesity are common risk factors for the development of OA. The common symptoms include pain and disability of the affected joint, leading to mobility issues. Read more about this study
- Who is it for?
- Ages 55 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Osteoarthritis, Type 2 Diabetes, Obesity
- What is being tested?
- Acetyl-l-carnitine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Dec 2025to 15 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 55-65 years
- Duration of menopause 2-15 years.
- Duration of diabetes 5-15 years
- BMI Obese ≥30 kg/m2
- Grade≥2 K\&L on radiologic examination
Who cannot join
- Female patients with osteoarthritis meeting the following criteria will be excluded from the study;
- Age˂55 ˃65yrs
- Post-menopausal duration of ˂2yrs
- Duration of diabetes ˂ 5years
- Patients with alcohol abuse, asthma, cardiac disease, chronic gastric problems (malabsorption, crohn's disease chronic diarrhea), non-diabetes related renal disease,ovariectomy, rheumatoid arthritis or other rheumatic inflammatory diseases, smoking
- Patients taking steroids (oral/ injections)
- Patients with a history of parathyroid and thyroid surgery/dysfunction
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Khalifa Gulnawaz Teaching Hospital, DHQ Teaching Hospital
Bannu, KPK, 28100
About this study
Official title: Effects of Acetyl L-Carnitine Supplementation on Clinical, Metabolic and Inflammatory Symptoms in Obese, Diabetic, Postmenopausal Women With Osteoarthritis: Randomized Controlled Trial
OA is a degenerative bone disease more common in postmenopausal women. Diabetes and obesity are common risk factors for the development of OA. The common symptoms include pain and disability of the affected joint, leading to mobility issues. Acetyl L-carnitine due to its known anti-inflammatory, chondroprotective, and improved insulin-sensitizing effects may help in alleviating the symptoms and progression of OA in obese diabetic postmenopausal women.
Read the detailed description
Osteoarthritis (OA) is a chronic degenerative joint disease that commonly affects older adults and is associated with pain, stiffness, reduced mobility, and disability. The coexistence of obesity and type 2 diabetes mellitus may aggravate the progression and severity of OA through metabolic dysfunction, chronic low-grade inflammation, oxidative stress, and altered adipokine profiles. Postmenopausal women are particularly vulnerable because hormonal changes contribute to increased inflammation, obesity, insulin resistance, and joint degeneration.
Acetyl L-Carnitine is a naturally occurring compound involved in mitochondrial energy metabolism. Previous studies have demonstrated anti-inflammatory, antioxidant, and metabolic benefits of Acetyl L-Carnitine, including improvements in insulin resistance, lipid metabolism, oxidative stress, and inflammatory cytokine production. Experimental studies have also suggested chondroprotective effects through enhancement of cartilage matrix synthesis and mitochondrial function.
This double-blind, placebo-controlled randomized clinical trial will enroll 100 obese, diabetic, postmenopausal women with radiologically confirmed osteoarthritis. Participants will be randomly assigned to receive either Acetyl L-Carnitine (1.5 g twice daily) or placebo for 12 weeks in addition to conventional osteoarthritis treatment.
Clinical outcomes will include assessment of osteoarthritis symptoms using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), radiological severity using the Kellgren-Lawrence grading system, perceived stress, and depression, anxiety and stress scores. Laboratory outcomes will include glycemic profile, lipid profile, insulin resistance markers, inflammatory biomarkers (CRP and IL-6), oxidative stress markers, adipokines, stress hormones, and complete blood count parameters.
The study seeks to determine whether Acetyl L-Carnitine supplementation can improve clinical, metabolic, inflammatory, and radiological outcomes in obese, diabetic, postmenopausal women with osteoarthritis.
- Conditions
- Osteoarthritis, Type 2 Diabetes, Obesity
- Being tested
- Acetyl-l-carnitine, Placebo
- Keywords
- Randomized Controlled Trial, Acetyl L-Carnitine, Postmenopausal Women, Oxidative Stress
- Medical subject headings
- Osteoarthritis, Diabetes Mellitus, Type 2, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acetyl-l-carnitineDrug
Also called ALCAR, L-Carnitine (if used locally)
Acetyl L-Carnitine capsules, 1.5 g administered orally twice daily (total daily dose 3 g) after meals for 12 weeks in addition to conventional osteoarthritis treatment.
PlaceboDrug
Also called Placebo capsules
Matching placebo capsules administered orally twice daily for 12 weeks in addition to conventional osteoarthritis treatment.
| Study group | Role | What they receive |
|---|---|---|
| Acetyl L-Carnitine Group | Experimental | Participants will receive conventional treatment for osteoarthritis, including NSAIDs, COX-2 inhibitors, or acetaminophen as prescribed, together with Acetyl L-Carnitine capsules 1.5 g orally twice daily (total daily dose 3 g) after meals for 12 weeks. Participants will continue their usual oral antihyperglycemic medications but will not receive insulin. Receives: Drug: Acetyl-l-carnitine |
| Placebo Control Group | Placebo comparator | Participants will receive matching placebo capsules administered orally at a dose of two capsules daily after meals for 12 weeks, in addition to conventional osteoarthritis treatment, including NSAIDs, COX-2 inhibitors, or acetaminophen as prescribed. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum C-Reactive Protein Concentration
Change in Serum C-Reactive Protein (CRP) Concentration (mg/L) from baseline following 12 weeks of Acetyl L-Carnitine supplementation.
Measured: Baseline and Week 12
Fasting Blood Glucose Concentration
Change in fasting blood glucose levels (mg/dL) from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Glycated Hemoglobin (HbA1c) Percentage
Change in HbA1c levels (%) from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Score from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Fasting Serum Insulin Concentration
Change in fasting serum insulin concentration (µIU/mL) from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Serum Leptin Concentration
Change in serum leptin concentration (ng/mL) from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Serum Adiponectin Concentration
Change in serum adiponectin concentration (µg/mL) from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Serum Adrenocorticotropic Hormone (ACTH) Concentration
Change in serum ACTH concentration from baseline following 12 weeks of intervention
Measured: Baseline and Week 12
Serum Malondialdehyde (MDA) Concentration
Change in serum malondialdehyde levels as a marker of oxidative stress from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Serum Advanced Glycation End Products (AGEs) Concentration
Change in serum AGEs levels from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
WOMAC Osteoarthritis Index total Score
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Kellgren-Lawrence Radiographic Grade
Change in osteoarthritis radiographic severity assessed by the Kellgren-Lawrence grading system from baseline following 12 weeks of intervention.
Measured: Baseline and Week 12
Secondary outcomes (1)
Interleukin-6 (IL-6)
Change in serum IL-6 concentration from baseline following 12 weeks of Acetyl L-Carnitine supplementation.
Measured: Baseline and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start1 Dec 2025
- Primary completion15 Jul 2026
- Study completion15 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to one of two parallel groups: conventional treatment plus placebo or conventional treatment plus Acetyl L-Carnitine (1.5 g twice daily) for 12 weeks. Outcomes will be assessed at baseline and after intervention.
- Masking
- Double blind
- Who is masked
- Care provider, Investigator
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Khyber Medical University Peshawar
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dr Safia Bibi, PhD*, Principal investigator, Khyber Medical University Peshawar, PakistanDr Mohsin Shah, PhD, Principal investigator, Khyber Medical University Peshawar, PakistanDr Zia Ullah, PhD, Principal investigator, Khalifa Gul Nawaz Teaching Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07660081
- Sponsor's protocol ID
- KMU/DIR/CTU/2026/05
- Status last verified
- Sep 2026
- First submitted
- 16 Jun 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying the results reported in publications arising from this study will be made available to qualified researchers upon reasonable request. Shared data may include demographic characteristics, clinical outcomes, biochemical measurements, inflammatory markers, hormonal markers, and questionnaire data collected during the study. All data will be de-identified before sharing to protect participant confidentiality.
Publications
GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7. eCollection 2023 Sep.
PubMed 37675071Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014 Sep;73(9):1659-64. doi: 10.1136/annrheumdis-2013-203355. Epub 2013 Jun 6.
PubMed 23744977Thijssen E, van Caam A, van der Kraan PM. Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. Rheumatology (Oxford). 2015 Apr;54(4):588-600. doi: 10.1093/rheumatology/keu464. Epub 2014 Dec 11.
PubMed 25504962Francisco V, Tovar S, Conde J, Pino J, Mera A, Lago F, Gonzalez-Gay MA, Dieguez C, Gualillo O. Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis. Nutrients. 2020 Apr 6;12(4):1006. doi: 10.3390/nu12041006.
PubMed 32268520Lu Q, Zhang Y, Elisseeff JH. Carnitine and acetylcarnitine modulate mesenchymal differentiation of adult stem cells. J Tissue Eng Regen Med. 2015 Dec;9(12):1352-62. doi: 10.1002/term.1747. Epub 2013 Apr 29.
PubMed 23625722Walker C, Faustino A, Lanas A. Monitoring complete blood counts and haemoglobin levels in osteoarthritis patients: results from a European survey investigating primary care physician behaviours and understanding. Open Rheumatol J. 2014 Dec 19;8:110-5. doi: 10.2174/1874312901408010110. eCollection 2014.
PubMed 25598854
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Acetyl L-Carnitine Supplementation on Clinical, Metabolic and Inflammatory Symptoms in Obese, Diabetic, Postmenopausal Women With Osteoarthritis: Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07660081
- Acronym / sponsor ID
- KMU/DIR/CTU/2026/05
- Conditions
- Osteoarthritis, Type 2 Diabetes, Obesity
- Keywords
- Randomized Controlled Trial, Acetyl L-Carnitine, Postmenopausal Women, Oxidative Stress
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Khyber Medical University PeshawarUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 15 Jul 2026 (actual)
- Study completion
- 15 Aug 2026 (actual)
- First posted
- 22 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
OA is a degenerative bone disease more common in postmenopausal women. Diabetes and obesity are common risk factors for the development of OA. The common symptoms include pain and disability of the affected joint, leading to mobility issues. Acetyl L-carnitine due to its known anti-inflammatory, chondroprotective, and improved insulin-sensitizing effects may help in alleviating the symptoms and progression of OA in obese diabetic postmenopausal women.
Detailed description
Osteoarthritis (OA) is a chronic degenerative joint disease that commonly affects older adults and is associated with pain, stiffness, reduced mobility, and disability. The coexistence of obesity and type 2 diabetes mellitus may aggravate the progression and severity of OA through metabolic dysfunction, chronic low-grade inflammation, oxidative stress, and altered adipokine profiles. Postmenopausal women are particularly vulnerable because hormonal changes contribute to increased inflammation, obesity, insulin resistance, and joint degeneration.
Acetyl L-Carnitine is a naturally occurring compound involved in mitochondrial energy metabolism. Previous studies have demonstrated anti-inflammatory, antioxidant, and metabolic benefits of Acetyl L-Carnitine, including improvements in insulin resistance, lipid metabolism, oxidative stress, and inflammatory cytokine production. Experimental studies have also suggested chondroprotective effects through enhancement of cartilage matrix synthesis and mitochondrial function.
This double-blind, placebo-controlled randomized clinical trial will enroll 100 obese, diabetic, postmenopausal women with radiologically confirmed osteoarthritis. Participants will be randomly assigned to receive either Acetyl L-Carnitine (1.5 g twice daily) or placebo for 12 weeks in addition to conventional osteoarthritis treatment.
Clinical outcomes will include assessment of osteoarthritis symptoms using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), radiological severity using the Kellgren-Lawrence grading system, perceived stress, and depression, anxiety and stress scores. Laboratory outcomes will include glycemic profile, lipid profile, insulin resistance markers, inflammatory biomarkers (CRP and IL-6), oxidative stress markers, adipokines, stress hormones, and complete blood count parameters.
The study seeks to determine whether Acetyl L-Carnitine supplementation can improve clinical, metabolic, inflammatory, and radiological outcomes in obese, diabetic, postmenopausal women with osteoarthritis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, investigator)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned to one of two parallel groups: conventional treatment plus placebo or conventional treatment plus Acetyl L-Carnitine (1.5 g twice daily) for 12 weeks. Outcomes will be assessed at baseline and after intervention.
| Arm | Type | Receives |
|---|---|---|
| Acetyl L-Carnitine Group | Experimental | Drug: Acetyl-l-carnitineParticipants will receive conventional treatment for osteoarthritis, including NSAIDs, COX-2 inhibitors, or acetaminophen as prescribed, together with Acetyl L-Carnitine capsules 1.5 g orally twice daily (total daily dose 3 g) after meals for 12 weeks. Participants will continue their usual oral antihyperglycemic medications but will not receive insulin. |
| Placebo Control Group | Placebo comparator | Drug: PlaceboParticipants will receive matching placebo capsules administered orally at a dose of two capsules daily after meals for 12 weeks, in addition to conventional osteoarthritis treatment, including NSAIDs, COX-2 inhibitors, or acetaminophen as prescribed. |
Who may qualify
- Ages
- 55 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 55-65 years
- Duration of menopause 2-15 years.
- Duration of diabetes 5-15 years
- BMI Obese ≥30 kg/m2
- Grade≥2 K\&L on radiologic examination
Key exclusion criteria (7 listed)
- Female patients with osteoarthritis meeting the following criteria will be excluded from the study;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acetyl-l-carnitineAlso: ALCAR, L-Carnitine (if used locally)Acetyl L-Carnitine capsules, 1.5 g administered orally twice daily (total daily dose 3 g) after meals for 12 weeks in addition to conventional osteoarthritis treatment. | Drug | Acetyl L-Carnitine Group |
| PlaceboAlso: Placebo capsulesMatching placebo capsules administered orally twice daily for 12 weeks in addition to conventional osteoarthritis treatment. | Drug | Placebo Control Group |
Primary outcome
Serum C-Reactive Protein Concentration
Time frame: Baseline and Week 12
Change in Serum C-Reactive Protein (CRP) Concentration (mg/L) from baseline following 12 weeks of Acetyl L-Carnitine supplementation.
Fasting Blood Glucose Concentration
Time frame: Baseline and Week 12
Change in fasting blood glucose levels (mg/dL) from baseline following 12 weeks of intervention.
Glycated Hemoglobin (HbA1c) Percentage
Time frame: Baseline and Week 12
Change in HbA1c levels (%) from baseline following 12 weeks of intervention.
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Time frame: Baseline and Week 12
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Score from baseline following 12 weeks of intervention.
Fasting Serum Insulin Concentration
Time frame: Baseline and Week 12
Change in fasting serum insulin concentration (µIU/mL) from baseline following 12 weeks of intervention.
Serum Leptin Concentration
Time frame: Baseline and Week 12
Change in serum leptin concentration (ng/mL) from baseline following 12 weeks of intervention.
Serum Adiponectin Concentration
Time frame: Baseline and Week 12
Change in serum adiponectin concentration (µg/mL) from baseline following 12 weeks of intervention.
Serum Adrenocorticotropic Hormone (ACTH) Concentration
Time frame: Baseline and Week 12
Change in serum ACTH concentration from baseline following 12 weeks of intervention
Serum Malondialdehyde (MDA) Concentration
Time frame: Baseline and Week 12
Change in serum malondialdehyde levels as a marker of oxidative stress from baseline following 12 weeks of intervention.
Serum Advanced Glycation End Products (AGEs) Concentration
Time frame: Baseline and Week 12
Change in serum AGEs levels from baseline following 12 weeks of intervention.
WOMAC Osteoarthritis Index total Score
Time frame: Baseline and Week 12
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline following 12 weeks of intervention.
Kellgren-Lawrence Radiographic Grade
Time frame: Baseline and Week 12
Change in osteoarthritis radiographic severity assessed by the Kellgren-Lawrence grading system from baseline following 12 weeks of intervention.
1 secondary outcome
Interleukin-6 (IL-6)
Time frame: Baseline and Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
- Background: PubMed 37675071GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7. eCollection 2023 Sep.
- Background: PubMed 23744977Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014 Sep;73(9):1659-64. doi: 10.1136/annrheumdis-2013-203355. Epub 2013 Jun 6.
- Background: PubMed 25504962Thijssen E, van Caam A, van der Kraan PM. Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. Rheumatology (Oxford). 2015 Apr;54(4):588-600. doi: 10.1093/rheumatology/keu464. Epub 2014 Dec 11.
- Background: PubMed 32268520Francisco V, Tovar S, Conde J, Pino J, Mera A, Lago F, Gonzalez-Gay MA, Dieguez C, Gualillo O. Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis. Nutrients. 2020 Apr 6;12(4):1006. doi: 10.3390/nu12041006.
- Background: PubMed 23625722Lu Q, Zhang Y, Elisseeff JH. Carnitine and acetylcarnitine modulate mesenchymal differentiation of adult stem cells. J Tissue Eng Regen Med. 2015 Dec;9(12):1352-62. doi: 10.1002/term.1747. Epub 2013 Apr 29.
- Background: PubMed 25598854Walker C, Faustino A, Lanas A. Monitoring complete blood counts and haemoglobin levels in osteoarthritis patients: results from a European survey investigating primary care physician behaviours and understanding. Open Rheumatol J. 2014 Dec 19;8:110-5. doi: 10.2174/1874312901408010110. eCollection 2014.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying the results reported in publications arising from this study will be made available to qualified researchers upon reasonable request. Shared data may include demographic characteristics, clinical outcomes, biochemical measurements, inflammatory markers, hormonal markers, and questionnaire data collected during the study. All data will be de-identified before sharing to protect participant confidentiality.
Related trials for Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr Safia Bibi, PhD* principal investigator
Khyber Medical University Peshawar, Pakistan
Dr Mohsin Shah, PhD principal investigator
Khyber Medical University Peshawar, Pakistan
Dr Zia Ullah, PhD principal investigator
Khalifa Gul Nawaz Teaching Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acetyl-l-carnitine in people with Osteoarthritis and Type 2 Diabetes, run by Khyber Medical University Peshawar at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum C-Reactive Protein Concentration (time frame: Baseline and Week 12). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07660081, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.